Proactiveinvestors USA & Canada Circassia Pharmaceuticals https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Circassia Pharmaceuticals RSS feed en Sun, 19 May 2019 11:38:58 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Annual report and notice of AGM ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190514162434_14073824/ Tue, 14 May 2019 11:24:34 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190514162434_14073824/ <![CDATA[RNS press release - Publication of Tudorza Phase IV ASCENT in JAMA ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190508070003_14065612/ Wed, 08 May 2019 02:00:03 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190508070003_14065612/ <![CDATA[RNS press release - Issue of Equity ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190503141812_14062972/ Fri, 03 May 2019 09:18:12 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190503141812_14062972/ <![CDATA[RNS press release - Final Results ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190501070009_14058432/ Wed, 01 May 2019 02:00:09 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190501070009_14058432/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190430070004_14056243/ Tue, 30 Apr 2019 02:00:04 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190430070004_14056243/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190415115535_14041380/ Mon, 15 Apr 2019 06:55:35 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190415115535_14041380/ <![CDATA[RNS press release - FDA approval of Duaklir for treatment of COPD ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190401070006_14022462/ Mon, 01 Apr 2019 02:00:06 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190401070006_14022462/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190329164036_14022132/ Fri, 29 Mar 2019 12:40:36 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190329164036_14022132/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190329163557_14022121/ Fri, 29 Mar 2019 12:35:57 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190329163557_14022121/ <![CDATA[RNS press release - FDA website posts Duaklir NDA approval ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190329155846_14022034/ Fri, 29 Mar 2019 11:58:46 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190329155846_14022034/ <![CDATA[RNS press release - Circassia announces FDA approval of Tudorza sNDA ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190329153448_14021993/ Fri, 29 Mar 2019 11:34:48 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190329153448_14021993/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190329070002_14020374/ Fri, 29 Mar 2019 03:00:02 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190329070002_14020374/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190305165319_13991224/ Tue, 05 Mar 2019 11:53:19 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190305165319_13991224/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190304160436_13989560/ Mon, 04 Mar 2019 11:04:36 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190304160436_13989560/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190228070006_13984396/ Thu, 28 Feb 2019 02:00:06 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190228070006_13984396/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190211171707_13965477/ Mon, 11 Feb 2019 12:17:07 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190211171707_13965477/ <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190208090002_13963142/ Fri, 08 Feb 2019 04:00:02 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190208090002_13963142/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190206164453_13960850/ Wed, 06 Feb 2019 11:44:53 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190206164453_13960850/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190206070003_13959537/ Wed, 06 Feb 2019 02:00:03 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190206070003_13959537/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190204175730_13957755/ Mon, 04 Feb 2019 12:57:30 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190204175730_13957755/ <![CDATA[RNS press release - Successful FDA Presubmission Meeting for AirNOvent ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190204080623_13956813/ Mon, 04 Feb 2019 03:06:23 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190204080623_13956813/ <![CDATA[RNS press release - Admission to AIM ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190204080617_13956812/ Mon, 04 Feb 2019 03:06:17 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190204080617_13956812/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190201163602_13956076/ Fri, 01 Feb 2019 11:36:02 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190201163602_13956076/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190201160337_13956030/ Fri, 01 Feb 2019 11:03:37 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190201160337_13956030/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190131070002_13952608/ Thu, 31 Jan 2019 02:00:02 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190131070002_13952608/ <![CDATA[RNS press release - Circassia Pharmaceuticals ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190130173001_13952475/ Wed, 30 Jan 2019 12:30:01 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190130173001_13952475/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190130164108_13952428/ Wed, 30 Jan 2019 11:41:08 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190130164108_13952428/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190130163540_13952419/ Wed, 30 Jan 2019 11:35:40 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190130163540_13952419/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190128153003_13949204/ Mon, 28 Jan 2019 10:30:03 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190128153003_13949204/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190125114941_13947371/ Fri, 25 Jan 2019 06:49:41 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190125114941_13947371/ <![CDATA[RNS press release - Commercial rights acquired from AIT Therapeutics ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190124070005_13944843/ Thu, 24 Jan 2019 02:00:05 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190124070005_13944843/ <![CDATA[RNS press release - Block listing Interim Review ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190118142240_13940046/ Fri, 18 Jan 2019 09:22:40 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190118142240_13940046/ <![CDATA[RNS press release - Result of General Meeting ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190104134801_13924575/ Fri, 04 Jan 2019 08:48:01 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190104134801_13924575/ <![CDATA[RNS press release - General Meeting Business Update ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20190104070004_13923572/ Fri, 04 Jan 2019 02:00:04 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20190104070004_13923572/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20181231070004_13918688/ Mon, 31 Dec 2018 02:00:04 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20181231070004_13918688/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20181227070009_13915800/ Thu, 27 Dec 2018 02:00:09 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20181227070009_13915800/ <![CDATA[RNS press release - Listing Rule 9.6.14(R) Disclosure ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20181217070006_13905332/ Mon, 17 Dec 2018 02:00:06 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20181217070006_13905332/ <![CDATA[RNS press release - Option exercised for Tudorza from AstraZeneca ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20181211121024_13899494/ Tue, 11 Dec 2018 07:10:24 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20181211121024_13899494/ <![CDATA[RNS press release - Posting of Shareholder Circular ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20181210175929_13898275/ Mon, 10 Dec 2018 12:59:29 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20181210175929_13898275/ <![CDATA[RNS press release - Proposed admission to trading on AIM ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20181210125937_13897879/ Mon, 10 Dec 2018 07:59:37 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20181210125937_13897879/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20181130070002_13886067/ Fri, 30 Nov 2018 02:00:02 -0500 https://www.proactiveinvestors.com/companies/rns/8408/LSE20181130070002_13886067/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20181031141338_13849868/ Wed, 31 Oct 2018 10:13:38 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20181031141338_13849868/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20181025150015_13842888/ Thu, 25 Oct 2018 10:00:15 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20181025150015_13842888/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20180928070002_13807895/ Fri, 28 Sep 2018 02:00:02 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20180928070002_13807895/ <![CDATA[RNS press release - Interim Results for Six Months Ended 30 June 2018 ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20180927070009_13806209/ Thu, 27 Sep 2018 02:00:09 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20180927070009_13806209/ <![CDATA[RNS press release - Notice of Interim Results and Broker Appointment ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20180907113603_13783229/ Fri, 07 Sep 2018 06:36:03 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20180907113603_13783229/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20180903121503_13776745/ Mon, 03 Sep 2018 07:15:03 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20180903121503_13776745/ <![CDATA[RNS press release - Director Declaration ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20180816162525_13758627/ Thu, 16 Aug 2018 11:25:25 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20180816162525_13758627/ <![CDATA[RNS press release - Regulatory Application ]]> https://www.proactiveinvestors.com/companies/rns/8408/LSE20180813070004_13752227/ Mon, 13 Aug 2018 02:00:04 -0400 https://www.proactiveinvestors.com/companies/rns/8408/LSE20180813070004_13752227/ <![CDATA[News - Circassia Pharma gets UK approval for asthma challenger ]]> https://www.proactiveinvestors.com/companies/news/119640/circassia-pharma-gets-uk-approval-for-asthma-challenger-119640.html Circassia Pharmaceuticals (LON:CIR) shares edged higher as its new asthma inhaler was recommended for a UK licence opening the way for marketing across Europe.

The UK regulator (MHRA) acted as a referee for the product, which will now be submitted under the Mutual Recognition Procedure for approval in other EU member states.

The marketing application includes all three strengths of fluticasone propionate where the current standard, GlaxoSmithKline’s Flixotide, is available and will be eligible for direct substitution of Glaxo’s product in countries that give approval.

Circassia added the positive regulatory outcome also represented an important validation of its particle-engineering platform in an area where products, and respiratory medicines especially, are difficult to manufacture.

It was the first time a marketing application for a respiratory product of different strengths had been approved using in vitro data only and without a clinical trial, the pharma company added.

Steve Harris, Circassia's chief executive, said: "Achieving this positive outcome is a major milestone for Circassia, marking the favourable conclusion of the company's first ever Marketing Authorisation Application for a product using its particle-engineering technology.

Circassia acquired the technology through its acquisition of Prosonix in June and it has been developed in collaboration with Dutch group Mylan.

Shares rose  6% to 280p.

]]>
Tue, 24 Nov 2015 12:27:00 -0500 https://www.proactiveinvestors.com/companies/news/119640/circassia-pharma-gets-uk-approval-for-asthma-challenger-119640.html